JAZZ Jazz Pharmaceuticals PLC

109.63

-3.49 (-3.09%)

11 May 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Jazz Pharmaceuticals PLC	NASDAQ:JAZZ	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-3.49	-3.09%	109.63	107.10	116.00	113.84	109.32	113.15	564,155	01:00:00

Jazz Pharmaceuticals Gets European Commission OK for Enrylaze

21/09/2023 11:20pm

Dow Jones News

Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart

From May 2023 to May 2024

Click Here for more Jazz Pharmaceuticals Charts.

By Ben Glickman

Jazz Pharmaceuticals on Thursday said it had received market authorization from the European Commission for its treatment for certain types of leukemia and lymphoma.

The Dublin-based pharmaceutical company said that Enrylaze could now be used as a component of a multi-agent chemotherapeutic regiment in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.

Enrylaze is currently approved under the name Rylaze in the U.S. and Canada.

The approval from the European Commission was based on Phase 2/3 trial data.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

September 21, 2023 18:05 ET (22:05 GMT)